TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Nona Biosciences and Evive Biotech Collaborate to Advance Antibody Discovery

Monday, December 11, 2023

Nona Biosciences and Evive Biotech have recently announced a collaboration focused on antibody discovery using Nona Biosciences' proprietary Harbour Mice® antibody technology platform. Nona Biosciences, a global innovator in technology and antibody development, is partnering with Evive Biotech, a biopharmaceutical company dedicated to creating novel biological therapies for global patients. The collaboration aims to expedite antibody discovery and drug development, ultimately providing faster benefits to patients.

The Harbour Mice® platform is a proprietary antibody technology that employs transgenic mice to produce fully human monoclonal antibodies in both traditional two heavy and two light chain (H2L2) format and a heavy chain only (HCAb) format. This technology holds substantial promise for therapeutic antibody development and expediting drug discovery.

Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, expressed the commitment to delivering superior and quicker antibody discovery and research solutions to partners, leveraging the capabilities of Harbour Mice®. The goal is to empower partners in antibody drug discovery and development, ultimately ensuring that more patients can benefit from cutting-edge technologies and therapies.

Simon Li, MD, PhD, CEO & CMO of Evive Biotech, highlighted the tremendous potential of antibody-based therapy and conveyed excitement about the collaboration. Evive Biotech's mission is to advance innovative biologic therapies globally, and they look forward to partnering with Nona Biosciences to expedite the discovery of groundbreaking antibody therapies for the benefit of patients worldwide.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit